|Bid||42.45 x 800|
|Ask||42.88 x 1000|
|Day's Range||39.65 - 43.10|
|52 Week Range||38.06 - 82.35|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2017 - Nov 20, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.00|
Zacks.com featured highlights include: LexinFintech, Herman Miller, Interactive Brokers, ConnectOne and Surmodics
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.
On a per-share basis, the Eden Prairie, Minnesota-based company said it had net income of 9 cents. Earnings, adjusted for non-recurring gains, were 7 cents per share. The drug delivery technology company ...
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2019 conference call on Wednesday, May 1, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon. Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will recap the second quarter fiscal 2019 financial results and accomplishments.
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Sublime™ guide sheath. “Surmodics continues to make progress in the development of clinically important and innovative technologies,” said Gary Maharaj, Surmodics President and CEO. Radial artery access has been widely adopted for use in coronary procedures where devices have been developed to accommodate that need.
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™ drug-coated balloon (DCB), was temporarily paused following the March 15 publication of a Food & Drug Administration (FDA) letter to physicians.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But when you pick a company that is really flourishing, you can make more than 100%. For exam...
Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Tim Arens, vice president of finance and chief financial officer, will make a presentation to the investment community at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, at 1:30 p.m. ET (12:30 p.m. CT). A live audio webcast of the presentation will be available by going to the investor relations portion of the Company’s website at https://surmodics.gcs-web.com, clicking on the webcast link and, on the conference's registration page, completing the required fields to register.
A Food and Drug Administration probe into chemotherapy drug paclitaxel is testing the waters for medical device companies SurModics, Boston Scientific, Medtronic and Becton Dickinson.
Surmodics Inc said in a securities filing Monday that it was working with the Food and Drug Administration to clarify how the agency's Friday warning about paclitaxel-coated balloons and paclitaxel-eluting stents would affect the company's clinical trial evaluating SurVeil, its drug-coated balloon for the treatment of peripheral artery disease. In the Monday filing, Surmodics said it was "currently assessing the impact of the FDA communication on the TRANSCEND clinical trial, its expectations regarding the timing of completion of patient enrollment in the TRANSCEND clinical trial and related regulatory approvals for the SurVeil DCB, and any corresponding effect on its fiscal 2019 financial guidance." The FDA first said in January that it would be evaluating the potential for increased long-term mortality after using paclitaxel-coated balloons and stents. On Friday, the agency said a preliminary analysis of three trials had "identified a potentially concerning signal of increased long-term mortality in study subjects treated with paclitaxel-coated products compared to patients treated with uncoated devices." The FDA's data followed a meta-analysis published in December in the Journal of the American Heart Association showing a possible increase in mortality after two years in patients treated with paclitaxel balloons or stents. Shares of Surmodics have gained 14% in the past three months, while the S&P 500 has gained 10.8%.